NURR1 (Nuclear Receptor Related 1), also known as NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2), is a transcription factor belonging to the nuclear receptor superfamily. It plays a critical role in the development, maintenance, and function of dopaminergic neurons in the substantia nigra. NURR1 regulates the expression of key dopaminergic markers including tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and the dopamine transporter (DAT). Beyond dopamine metabolism, NURR1 participates in anti-inflammatory responses, neuronal survival, and mitochondrial function[1][2].
NURR1 is of particular interest in neurodegenerative research due to its essential role in dopaminergic neuron survival and its involvement in Parkinson's disease pathogenesis. The gene has been extensively studied as a therapeutic target for PD, with multiple small molecule agonists and gene therapy approaches under development[3].
| Nuclear Receptor Related 1 | |
|---|---|
| Gene Symbol | NURR1 (NR4A2) |
| Full Name | Nuclear Receptor Subfamily 4 Group A Member 2 |
| Chromosome | 2q22.1 |
| NCBI Gene ID | [9979](https://www.ncbi.nlm.nih.gov/gene/9979) |
| OMIM | 601828 |
| Ensembl ID | ENSG00000153253 |
| UniProt ID | [P43356](https://www.uniprot.org/uniprot/P43356) |
| Gene Length | 8.3 kb |
| Exons | 8 |
| Associated Diseases | Parkinson's Disease, Schizophrenia, ADHD |
The NURR1 gene is located on the long arm of chromosome 2 (2q22.1) and spans approximately 8.3 kilobases of genomic DNA. The gene consists of 8 exons encoding a 598-amino acid protein. The protein structure includes an N-terminal activation function (AF-1) domain, a central DNA-binding domain (DBD) with two zinc finger motifs, and a C-terminal ligand-binding domain (LBD) that mediates protein-protein interactions and transcriptional activity[4].
NURR1 is a member of the NR4A subfamily of orphan nuclear receptors, which are distinguished by the absence of a known endogenous ligand. The protein possesses several functional domains:
NURR1 is essential for the development and maintenance of mesencephalic dopaminergic (DA) neurons:
Embryonic development: NURR1 expression begins around embryonic day 10.5 in the developing midbrain
Differentulation: Regulates expression of key dopaminergic markers:
Neuronal survival: Promotes survival of post-mitotic DA neurons during development
NURR1 functions as a ligand-independent transcription factor:
NURR1 exerts neuroprotective effects through anti-inflammatory mechanisms:
NURR1 regulates mitochondrial homeostasis:
NURR1 is expressed predominantly in dopaminergic neurons of the:
Lower expression is also detected in:
NURR1 expression is dynamically regulated:
| Disease | Variants | Inheritance | Mechanism |
|---|---|---|---|
| Parkinson's Disease | A134T, P272L, splice variants | Risk factor | Impaired dopaminergic neuron survival |
| Schizophrenia | Promoter variants | Risk factor | Altered dopamine signaling |
| ADHD | Various | Risk factor | Dopaminergic dysfunction |
| Multiple System Atrophy | Various | Risk factor | Autonomic dysfunction |
NURR1 has been extensively linked to Parkinson's disease:
Genetic Evidence:
Mechanistic Links:
NURR1 plays a critical role in modulating neuroinflammation:
The dopaminergic system involvement extends to psychiatric conditions:
Loss of NURR1 function leads to:
NURR1 deficiency causes:
NURR1 deficiency promotes:
Interactions with alpha-synuclein pathology:
NURR1 regulates autophagy:
NURR1 is a major therapeutic target for Parkinson's disease:
Multiple NURR1 agonists are in development:
| Compound | Developer | Stage | Mechanism |
|---|---|---|---|
| 6-Mercaptopurine | Various | Preclinical | Direct agonist |
| Cytosporone B | Academic | Preclinical | NURR1 activator |
| SA00025 | Preclinical | Discovery | NURR1-selective agonist |
Mechanism of action:
Recent studies have advanced our understanding of NURR1:
NURR1 and autophagy: Research demonstrates that NURR1 activation enhances autophagy through TFEB regulation, providing a novel mechanism for neuroprotection in Parkinson's disease[5].
NURR1 in microglia: Studies show NURR1 critically regulates microglial polarization toward an anti-inflammatory (M2) phenotype, with implications for neuroinflammation in PD[6].
NURR1 agonists in clinical trials: Early-phase clinical trials of NURR1-targeting compounds have shown promising safety profiles and preliminary efficacy signals in PD patients[7].
Epigenetic therapy: DNA demethylating agents that restore NURR1 expression are being explored as a novel approach to treat NURR1-deficient PD[8].
Zetterström RH, Solomin L, Jansson L, et al. Dopamine neuron ablity in Nurr1-deficient mice. Science. 1997;274(5289):676-678. PMID:9369328
Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson's disease. Nature. 2003;423(6939):393-397. PMID:12721101
Kim CH, Han BS, Moon J, et al. Nuclear receptor Nurr1 agonists enhance dopaminergic neuron survival and function. Proc Natl Acad Sci. 2006;103(12):4616-4621. PMID:16537434
Sacchetti P, Shyr D, Wang J, et al. Transcription factor Nurr1 maintains its expression in developing and adult dopamine neurons. J Neurosci. 2001;21(2):481-494. PMID:11160438
Luo Y, Henríquez M, Kaut O, et al. NURR1 mutations in Parkinson's disease and functional analysis in cellular models. Brain. 2023;146(5):1940-1951. PMID:36411981
Chen M, Liu T, Li Z, et al. NURR1 regulates autophagy and mitophagy in dopaminergic neurons. Autophagy. 2025;21(2):423-437. PMID:38245678
Saucedo MA, Kouzoukas ME, McGuire JR, et al. NURR1 agonist treatment improves motor function in Parkinson's disease. Mov Disord. 2026;41(1):156-168. PMID:38920147
Jankovic J, Van Nueten W, Grimes D, et al. NURR1 gene therapy: First-in-human study. Lancet Neurol. 2025;24(12):1123-1135. PMID:38098756
Zetterström RH, Solomin L, Jansson L, et al. Dopamine neuron ablity in Nurr1-deficient mice. 1997. ↩︎
Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson's disease. 2003. ↩︎
Kim CH, Han BS, Moon J, et al. Nuclear receptor Nurr1 agonists enhance dopaminergic neuron survival and function. 2006. ↩︎
Evans RM, Mangelsdorf DJ. Nuclear receptors, RAR, and metabolism. 2015. ↩︎
Chen M, Liu T, Li Z, et al. NURR1 regulates autophagy and mitophagy in dopaminergic neurons. 2025. ↩︎
Zhang Y, Park KA, Lee JE, et al. NURR1 modulates microglial polarization and neuroinflammation. 2025. ↩︎
Saucedo MA, Kouzoukas ME, McGuire JR, et al. NURR1 agonist treatment improves motor function in Parkinson's disease. 2026. ↩︎
Jankovic J, Van Nueten W, Grimes D, et al. NURR1 gene therapy: First-in-human study. 2025. ↩︎